The Current Ratio as of December 2024 (TTM) for Cardiff Oncology, Inc. (CRDF) is 4.74

According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.74. This represents a change of -17.73% compared to the average of 5.76 of the last 4 quarters.

Cardiff Oncology, Inc. (CRDF) Historical Current Ratio (quarterly & annually)

How has CRDF Current Ratio performed in the past?

The mean historical Current Ratio of Cardiff Oncology, Inc. over the last ten years is 9.42. The current 4.74 Current Ratio has changed 4.93% with respect to the historical average. Over the past ten years (40 quarters), CRDF's Current Ratio was at its highest in in the June 2021 quarter at 31.20. The Current Ratio was at its lowest in in the June 2017 quarter at 1.16.

Cardiff Oncology, Inc. (CRDF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cardiff Oncology, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cardiff Oncology, Inc. (CRDF) Average Current Ratio

How has CRDF Current Ratio performed in the past?

The current Current Ratio of Cardiff Oncology, Inc. (CRDF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cardiff Oncology, Inc. (CRDF) Current Ratio vs. Peers

How is CRDF’s Current Ratio compared to its peers?

Cardiff Oncology, Inc.’s Current Ratio is greater than Reviva Pharmaceuticals Holdings, Inc. (0.39), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than PDS Biotechnology Corporation (2.84), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Reviva Pharmaceuticals Holdings, Inc. (0.39), greater than Eyenovia, Inc. (0.74), greater than Cognition Therapeutics, Inc. (2.11), greater than TransCode Therapeutics, Inc. (1.58), less than Kodiak Sciences Inc. (8.42), greater than SELLAS Life Sciences Group, Inc. (2.26), greater than NLS Pharmaceutics AG (0.15), less than Mereo BioPharma Group plc (6.10), greater than Aravive, Inc. (0.98), less than Day One Biopharmaceuticals, Inc. (14.62), greater than IN8bio, Inc. (1.84), greater than Cue Biopharma, Inc. (2.22), less than Lantern Pharma Inc. (8.31), less than Gracell Biotechnologies Inc. (7.73), less than Cullinan Oncology, Inc. (24.46), greater than Bolt Biotherapeutics, Inc. (3.16), greater than Lyra Therapeutics, Inc. (3.64), less than Autolus Therapeutics plc (13.69),

Build a custom stock screener for Cardiff Oncology, Inc. (CRDF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cardiff Oncology, Inc. (CRDF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.